Brief: Ensysce Biosciences Announces First Patients Enrolled In Phase 1 Study Of Pf614-Mpar
15/12/2021 21:42
Dec 15 (Reuters) - Ensysce Biosciences Inc ENSC.O :
* ENSYSCE BIOSCIENCES ANNOUNCES FIRST PATIENTS ENROLLED IN
PHASE 1
STUDY OF PF614-MPAR™, ITS UNIQUE TECHNOLOGY PLATFORM TO PROVIDE
OPIOID OVERDOSE PROTECTION
Source text for Eikon: ID:nGNX7WmrNw
Further company coverage: ENSC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ensysce Biosciences
See all newsEnsysce Biosciences Q2 net loss widens on higher R&D costs
Ensysce Biosciences Inc expected to post a loss of 50 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Ensysce Biosciences Launches Formal Review Of Strategic Alternatives - SEC Filing